173 related articles for article (PubMed ID: 22494439)
1. 3D-QSAR studies on UDP-glucuronosyltransferase 2B7 substrates using the pharmacophore and VolSurf approaches.
Ako R; Dong D; Wu B
Xenobiotica; 2012 Sep; 42(9):891-900. PubMed ID: 22494439
[TBL] [Abstract][Full Text] [Related]
2. Establishment of pharmacophore and VolSurf models to predict the substrates of UDP-glucuronosyltransferase1A3.
Wu Z; Zhang X; Ma Z; Wu B
Xenobiotica; 2015; 45(8):653-62. PubMed ID: 25837689
[TBL] [Abstract][Full Text] [Related]
3. In silico modeling of UDP-glucuronosyltransferase 1A10 substrates using the VolSurf approach.
Dong D; Wu B
J Pharm Sci; 2012 Sep; 101(9):3531-9. PubMed ID: 22388963
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
J Med Chem; 2003 Apr; 46(9):1617-26. PubMed ID: 12699380
[TBL] [Abstract][Full Text] [Related]
5. Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Cianchetta G; Mannhold R; Cruciani G; Baroni M; Cecchetti V
J Med Chem; 2004 Jun; 47(12):3193-201. PubMed ID: 15163198
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.
Sorich MJ; Smith PA; McKinnon RA; Miners JO
Pharmacogenetics; 2002 Nov; 12(8):635-45. PubMed ID: 12439224
[TBL] [Abstract][Full Text] [Related]
7. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
[TBL] [Abstract][Full Text] [Related]
8. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.
Ekins S; Bravi G; Ring BJ; Gillespie TA; Gillespie JS; Vandenbranden M; Wrighton SA; Wikel JH
J Pharmacol Exp Ther; 1999 Jan; 288(1):21-9. PubMed ID: 9862748
[TBL] [Abstract][Full Text] [Related]
10. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance.
Ekins S; Obach RS
J Pharmacol Exp Ther; 2000 Nov; 295(2):463-73. PubMed ID: 11046077
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling, virtual screening and 3D-QSAR studies of 5-tetrahydroquinolinylidine aminoguanidine derivatives as sodium hydrogen exchanger inhibitors.
Bhatt HG; Patel PK
Bioorg Med Chem Lett; 2012 Jun; 22(11):3758-65. PubMed ID: 22546667
[TBL] [Abstract][Full Text] [Related]
13. Stereochemical and steric control of the UDP-glucuronosyltransferase-catalyzed conjugation reaction: a rational approach for the design of inhibitors for the human UGT2B7.
Bichlmaier I; Finel M; Sippl W; Yli-Kauhaluoma J
ChemMedChem; 2007 Dec; 2(12):1730-40. PubMed ID: 17943712
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
Thondorf I; Voigt V; Schäfer S; Gebauer S; Zebisch K; Laug L; Brandsch M
Bioorg Med Chem; 2011 Nov; 19(21):6409-18. PubMed ID: 21955456
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modelling and atom-based 3D-QSAR studies on N-methyl pyrimidones as HIV-1 integrase inhibitors.
Reddy KK; Singh SK; Dessalew N; Tripathi SK; Selvaraj C
J Enzyme Inhib Med Chem; 2012 Jun; 27(3):339-47. PubMed ID: 21699459
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
17. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity.
Sorich MJ; Miners JO; McKinnon RA; Smith PA
Mol Pharmacol; 2004 Feb; 65(2):301-8. PubMed ID: 14742671
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors.
Zhang J; Pan X; Wang C; Wang F; Li P; Xu W; He L
Chem Biol Drug Des; 2012 Mar; 79(3):353-9. PubMed ID: 22222003
[TBL] [Abstract][Full Text] [Related]
19. Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation.
Lewis BC; Mackenzie PI; Elliot DJ; Burchell B; Bhasker CR; Miners JO
Biochem Pharmacol; 2007 May; 73(9):1463-73. PubMed ID: 17223084
[TBL] [Abstract][Full Text] [Related]
20. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
